212 related articles for article (PubMed ID: 12395333)
1. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
Hepatology; 2004 Dec; 40(6):1361-9. PubMed ID: 15565568
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
Manesis EK; Giannoulis G; Zoumboulis P; Vafiadou I; Hadziyannis SJ
Hepatology; 1995 Jun; 21(6):1535-42. PubMed ID: 7768497
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
Barbare JC; Bouché O; Bonnetain F; Raoul JL; Rougier P; Abergel A; Boige V; Denis B; Blanchi A; Pariente A; Milan C; Bedenne L
J Clin Oncol; 2005 Jul; 23(19):4338-46. PubMed ID: 15994145
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.
Elba S; Giannuzzi V; Misciagna G; Manghisi OG
Ital J Gastroenterol; 1994 Mar; 26(2):66-8. PubMed ID: 8032079
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
9. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma.
Gallo C; De Maio E; Di Maio M; Signoriello G; Daniele B; Pignata S; Annunziata A; Perrone F;
BMC Cancer; 2006 Jul; 6():196. PubMed ID: 16863588
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients with hepatocellular carcinoma received surgical resection.
Lee LJ; Chen CH; Yao G; Chung CW; Sheu JC; Lee PH; Tsai YJ; Wang JD
J Surg Oncol; 2007 Jan; 95(1):34-9. PubMed ID: 17192864
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
16. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
17. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
[TBL] [Abstract][Full Text] [Related]
18. [Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation].
Wang YB; Chen MH; Yan K; Yang W; Dai Y; Yin SS
Ai Zheng; 2005 Jul; 24(7):827-33. PubMed ID: 16004809
[TBL] [Abstract][Full Text] [Related]
19. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
20. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
